Improved contrast sensitivity · participants with acute or chronic CME following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · participants with acute or chronic CME following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistence of visual improvement one month after discontinuation of treatment · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in leakage on FFA Â · participants with acute CME (< 4 months) following cataract surgery
It is very uncertain whether NSAID changes improvement in leakage on FFA Â compared with placebo or active control (very low certainty).
1 finding from 1 review
Improvement in central macular thickness on OCT · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improved contrast sensitivity · participants with acute CME (< 4 months) following cataract surgery
It is very uncertain whether NSAID changes improved contrast sensitivity  compared with placebo or active control (very low certainty).
1 finding from 1 review
QoL · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Pregabalin showed no clear difference in 50% or greater reduction in seizurefrequency compared with active comparators (low certainty).
3 findings from 1 review
RR 1.03 [0.85, 1.25]
3 studies · 1286 participants
Low
RR 1.6 [1.17, 2.19]
3 studies · 1286 participants
Very low
RR 0.67 [0.62, 0.74]
3 studies · 1286 participants
Moderate
Seizure freedom · people with drug‐resistant focal epilepsy
It is very uncertain whether pregabalin changes seizure freedom compared with active comparators (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Pregabalin showed no clear difference in treatment withdrawal for any reason compared with active comparators (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
1 finding from 1 review
Ataxia · people with drug‐resistant focal epilepsy
1 finding from 1 review
Dizziness · people with drug‐resistant focal epilepsy
1 finding from 1 review
Adverse effect: fatigue · people with drug‐resistant focal epilepsy
1 finding from 1 review
Adverse effects: headache · people with drug‐resistant focal epilepsy
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
1 finding from 1 review
Weight gain · people with drug‐resistant focal epilepsy
1 finding from 1 review
Interventions versus comparisons
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of bleeding
1 finding from 1 review